Catalog No.
DHJ72802
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-Kappa
Clonality
Monoclonal
Target
FIL1D, Interleukin-1 family member 5, IL-36Ra, IL1HY1, Interleukin-36 receptor antagonist protein, IL1RP3, IL-1RP3, IL-1ra homolog 1, Interleukin-1-like protein 1, IL-1-related protein 3, IL1L1, Interleukin-1 HY1, IL-1HY1, Interleukin-1 delta, FIL1 delta, IL-1 delta, IL-1L1, Interleukin-1 receptor antagonist homolog 1, IL36RN, IL1F5, IL-1F5
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9UBH0
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ANB-019, CAS: 2102543-86-0
Clone ID
Imsidolimab
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease, PMID: 33919434
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives, PMID: 33538202
New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors., PMID:39065604
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis., PMID:38438782
Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa., PMID:38397412
The expanding horizon of anti-IL-36 therapy., PMID:38296196
Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation., PMID:37838256
Imsidolimab for the treatment of generalized pustular psoriasis., PMID:37459129
Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials., PMID:37121476
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial., PMID:37120722
Imsidolimab: an emerging biological therapy for generalized pustular psoriasis., PMID:37079741
Targeting IL-36 in Inflammatory Skin Diseases., PMID:36867370
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications., PMID:36012744
Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors., PMID:35695278
A review of IL-36: an emerging therapeutic target for inflammatory dermatoses., PMID:35470744
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease., PMID:33919434
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives., PMID:33538202
For research use only. Not for human or drug use.
